Condition
Colorectal Cancer With Hepatic Metastases
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
5Total
P 1 (2)
P 2 (3)
Trial Status
Terminated2
Completed2
Not Yet Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04166383Phase 2Terminated
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
NCT07357220Phase 1Not Yet RecruitingPrimary
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
NCT03366155Phase 2Completed
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
NCT06834399Phase 2TerminatedPrimary
TATE and KN046 in MCRC
NCT01437007Phase 1CompletedPrimary
TKM 080301 for Primary or Secondary Liver Cancer
Showing all 5 trials